Name (Synonyms) | Correlation | |
---|---|---|
drug2055 | Parents and Infants Engaged Wiki | 0.71 |
drug2031 | PLACEBO Wiki | 0.50 |
There are 2 clinical trials
The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2. The specific objectives are to assess whether, in patients with mild and moderate forms of SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of: i) decrease viral load; ii) modify inflammatory parameters, such as cytokines, measured from serum; iii) reduce clinical and emotional symptoms through daily clinical evaluation; iv) improve sleep; v) reduce hospitalization and worsen the severity of the disease; v) Monitor the possible adverse effects of CBD use in these patients.
Description: Mean reduction in viral load (reduction of ≥1 log10) over time during the study period
Measure: Reduction in viral load Time: Up to 28 daysDescription: Clinical CoVid19 symptoms improvement
Measure: Number of participants with negative Clinical CoVid19 symptoms as assessed by CTCAE v5.0 Time: Up to 28 daysDescription: Immune reaction
Measure: Change in proinflammatory cytokine concentration Time: Up to 28 daysDescription: A qualitative CT analysis of parenchymal lung damage induced by COVID-19
Measure: Describe the parenchymal lung damage induced by COVID-19 through a qualitative analysis with chest CT Time: 14 daysDescription: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: Up to 28 daysDescription: Time to clinical improvement
Measure: Time to clinical improvement with CTCAE v5.0 CoVid19 symptoms to 0 Time: Up to 28 daysDescription: CoVid severity worsening
Measure: Number of participants that need hospitalisation Time: Up to 28 daysDescription: Mortality
Measure: 28-day mortality Time: Up to 28 daysDescription: Time to negative saliva
Measure: Time to negative saliva 2019-n-CoV RT-PCR Time: Up to 28 daysThe objective of this work is to monitor the level of stress and overload of a group of front-line health workers (physicians, nurses and physiotherapists) who will participate in the care of patients with COVID-19 at Hospital das Clínicas in Ribeirão Preto and its Emergency Unit (HCRP), for four weeks, and evaluate the cannabidiol - CBD's effectiveness in reducing stress for those who wish to use it.
Description: To assess the emotional exhaustion dimension of the burnout syndrome, based on nine items, scored from 0 ("never") to 6 ("every day")
Measure: aMBI-HSS: Abbreviated Maslach Burnout Inventory - Human Services Survey Time: Through study completion, over time during the study period (day 0-28)Description: It is a self-report measure widely used to assess PTSD symptoms, according to the DSM-5 criteria. The reduced version of this instrument will be used (8 items)
Measure: Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) Time: Through study completion, over time during the study period (day 0-28)Description: brief measure for assessing generalized anxiety disorder
Measure: Brief measure for assessing generalized anxiety disorder: The GAD‐7 Time: Through study completion, over time during the study period (day 0-28)Description: Evaluate depressive symptoms o
Measure: PHQ-9: Patient´s Health Questionnaire-9 Time: Through study completion, over time during the study period (day 0-28)Description: Laboratory parameters, including the change in proinflammatory cytokine concentrations
Measure: Change in proinflammatory cytokine concentration Time: Through study completion, over time during the study period (day 0-28)Description: Occurrence of side effects
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: Through study completion, over time during the study period (day 0-28)